Eupraxia Pharmaceuticals Inc (EPRX) Stock Price, Quote & News

Latest News on EPRX

Apr 24, 2025, 5:00 PM EDT - 2 days ago

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Mar 20, 2025, 5:31 PM EDT - 5 weeks ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Feb 25, 2025, 7:00 AM EST - 2 months ago

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Feb 18, 2025, 7:00 AM EST - 2 months ago

Eupraxia Pharmaceuticals Announces CFO Succession

Nov 20, 2024, 7:00 AM EST - 5 months ago

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Nov 14, 2024, 5:00 PM EST - 5 months ago

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Nov 13, 2024, 5:00 PM EST - 5 months ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Nov 12, 2024, 5:56 PM EST - 5 months ago

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Nov 7, 2024, 5:00 PM EST - 6 months ago

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 7:36 PM EDT - 6 months ago

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Oct 28, 2024, 7:00 AM EDT - 6 months ago

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Oct 15, 2024, 7:00 AM EDT - 6 months ago

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Oct 10, 2024, 7:00 AM EDT - 7 months ago

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Oct 2, 2024, 5:01 PM EDT - 7 months ago

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Sep 19, 2024, 5:00 PM EDT - 7 months ago

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

Sep 11, 2024, 7:00 AM EDT - 8 months ago

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Sep 4, 2024, 7:00 AM EDT - 8 months ago

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 5:00 PM EDT - 9 months ago

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 2, 2024, 7:00 AM EDT - 9 months ago

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

Jul 8, 2024, 7:00 AM EDT - 10 months ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Jul 3, 2024, 5:00 PM EDT - 10 months ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

Jun 6, 2024, 5:00 PM EDT - 11 months ago

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Jun 5, 2024, 7:00 AM EDT - 11 months ago

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 22, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

May 21, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 14, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

May 8, 2024, 5:03 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Apr 5, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today

Apr 3, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

Apr 1, 2024, 5:01 PM EDT - 1 year ago

Market Cap	138.02M
Revenue (ttm)	0.00
Net Income (ttm)	-25.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	24,700
Avg Vol	17,462
Day's Range	N/A - N/A
Shares Out	35.85M
Stochastic %K	82%
Beta	N/A
Analysts	Strong Sell
Price Target	$11.00